Showing results (351-360 of 615) with videos related to

Sort By:
Pageof 62
Experimental Hematology|November 1, 1979
Allogeneic marrow grafting for acute leukemia: a follow-up of long-term survivorsP S Stewart, C D Buckner, R A Clift, et al.
International Journal of Radiation Oncology, Biology, Physics|May 20, 1993
Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine modelR Storb, R F Raff, T Graham, et al.
Blood|August 1, 1990
Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogsF G Schuening, R Storb, S Goehle, et al.
Bone Marrow Transplantation|July 1, 1989
Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remissionW Bensinger, F B Petersen, M Banaji, et al.
Blood|October 1, 1986
Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donorsR F Raff, H J Deeg, T P Loughran, et al.
The American Journal of Pediatric Hematology/Oncology|February 1, 1994
Marrow transplant experience for children with severe aplastic anemiaJ E Sanders, R Storb, C Anasetti, et al.
Blood|March 15, 1995
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factorW I Bensinger, C H Weaver, F R Appelbaum, et al.
Human Gene Therapy|January 1, 1996
Long-term persistence of canine hematopoietic cells genetically marked by retrovirus vectorsH P Kiem, B Darovsky, C Von Kalle, et al.
Bone Marrow Transplantation|April 1, 1996
Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantationC Yu, R Storb, H J Deeg, et al.
Bone Marrow Transplantation|March 1, 1996
Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levelsT Demirer, C D Buckner, F R Appelbaum, et al.
Pageof 62